Targeted Therapy

Helical APBI Delivers Targeted Dose of Adjuvant Radiation Treatment for Breast Cancer

Helical APBI Delivers Targeted Dose of Adjuvant Radiation Treatment for Breast Cancer

By

Preliminary results of a prospective, phase II trial show that once-daily accelerated partial breast irradiation (APBI) effectively prevented recurrence of cancer in the treated breast at a median 34 months after treatment.

Rare Mutations in Immune-Related Genes Linked to Multiple Simultaneous Colorectal Cancer Tumors

By

Genetic mutations affecting the immune system were identified in patients who develop more than one CRC tumor at the same time, and understanding how these cancers develop could improve therapy targeting.

Surgery Improves Survival in Metastatic Kidney Cancer, But Is Little Used

By

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only approximately 3 in 10 such patients undergo the procedure.

Focal Laser Ablation Feasible and Safe for Treatment of Prostate Cancer

Focal Laser Ablation Feasible and Safe for Treatment of Prostate Cancer

By

Laser heat may soon be an option to treat prostate cancer. Focal laser ablation has been found both feasible and safe in men with intermediate risk prostate cancer.

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

By

Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).

DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer

DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer

By

Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.

Outcomes in Clinical Trials Using Precision Medicine Demonstrate Effectiveness of Modality in Patients With Cancer

By

A meta-analysis of hundreds of cancer clinical trials revealed that therapeutic approaches using precision medicine had improved responses and longer disease remission, even in phase I trials.

Alterations in Metabolic Pathways in Prostate Cancer Hint at Potential New Treatments

Alterations in Metabolic Pathways in Prostate Cancer Hint at Potential New Treatments

By

Castration-resistant prostate cancer (CRPC) has specific metabolic characteristics that could make it susceptible to new options for treatment.

Palbociclib Demonstrates Efficacy in Acute Myeloid Leukemia

By

The FLT3 tyrosine kinase is the most frequent mutation found in AML, and targeting CDK6 with palbociclib may be an effective strategy against AML.

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

By

The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.

Utidelone Plus Capecitabine Active in Patients Heavily Pretreated for Metastatic Breast Cancer

Utidelone Plus Capecitabine Active in Patients Heavily Pretreated for Metastatic Breast Cancer

By

The genetically engineered epothilone analog, utidelone, in combination with capecitabine significantly improved progression-free survival and objective response rates in patients with metastatic breast cancer who were heavily pretreated, compared with capecitabine alone, results of a phase 3 trial presented at the 2016 ASCO Annual Meeting have shown.

RET Inhibitors Active in Proportion of Patients with RET-Rearranged NSCLC

RET Inhibitors Active in Proportion of Patients with RET-Rearranged NSCLC

By

The largest database on outcomes with RET-directed therapy for RET-rearranged NSCLC to date confirms RET inhibitors are active in a proportion of patients, a study presented at the 2016 ASCO Annual Meeting has shown.

CDK4/6 Inhibitor Allows Sustained Dosing for Targeted Inhibition in 5 Solid Tumor Cancer Types

CDK4/6 Inhibitor Allows Sustained Dosing for Targeted Inhibition in 5 Solid Tumor Cancer Types

By

Abemaciclib, an investigational cancer therapeutic, showed durable clinical activity as a continuous single-agent therapy, according to results of a phase 1 trial with 5 tumor-specific cohorts.

Experimental Targeted Therapy Succeeds in Rare Pediatric Cancer

By

The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.

Gene Alterations May Explain Treatment Resistance of Triple-negative Breast Cancer

Gene Alterations May Explain Treatment Resistance of Triple-negative Breast Cancer

By

Amplification of the JAK2 gene frequently occurs in triple-negative breast cancer (TNBC), suggesting that specific inhibitors of JAK2 should be investigated in TNBC.

New Mechanism to Target RAS Genes Identified

New Mechanism to Target RAS Genes Identified

By

A small molecule that inhibits RAS protein interactions offers hope for targeting this elusive protein. It is one of the most sought-after cancer targets for drug developers, but the mutant RAS protein lacks drug-binding pockets.

Microneedle Patch Delivers Localized Immunotherapy for Melanoma

By

Microneedles embedded in a patch deliver cancer immunotherapy treatment directly to the site of melanoma, according to preliminary findings in animal studies.

Presurgical Treatment in HER2-positive Breast Cancer Achieves Significant Reduction in Disease

By

Treatment with lapatinib and trastuzumab before surgery and chemotherapy led to significant shrinkage or disappearance of the tumors in approximately 25% of women with HER2-positive breast cancer.

Cell Growth Inhibitor Overcomes Therapy Resistance and Delays Tumor Recurrence in Breast Cancer

By

Cyclin D1/CDK4 inhibitor treatment overcame resistance to targeted therapy in transgenic mouse models, cell cultures, and human tissue samples of HER2-positive breast cancer.

Targeted Radiation Holds Promise for Early Breast Cancer

Targeted Radiation Holds Promise for Early Breast Cancer

By

Limited radiotherapy effective after low-risk tumors are removed, but questions remain.

Interactions of Cancer-causing Gene May Lead to Therapeutic Target

By

An exploration of the interaction between the protein produced by the common cancer-causing KRAS gene and the AGO2 protein may lead to the possibility of interrupting the KRAS-AGO2 interaction as a possible therapy.

HER2-associated Lung Cancer: Mutations and Amplifications Result in Different Cancers

By

Two distinct causes of HER2 activation in lung cancer were demonstrated in a recent study. These findings imply that HER2-positive lung cancer may need different targeted therapies to combat these related but possibly distinct diseases.

Targeted Hormone-radiation Treatment Shows Promise in Midgut Neuroendocrine Tumors

By

Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.

CDK4/6 Inhibitors Exploit a Unique Vulnerability in Pancreatic Cancer

CDK4/6 Inhibitors Exploit a Unique Vulnerability in Pancreatic Cancer

By

The metabolism of pancreatic cancer cells is altered by the anticancer activity of CDK4/6 inhibitors. Researchers hope this biologic vulnerability could be exploited to treat pancreatic cancer.

Genomic Analysis Reveals Potential Therapeutic Options for Breast Cancer

Genomic Analysis Reveals Potential Therapeutic Options for Breast Cancer

By

Dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations have been suggested by the largest analysis of breast cancer cell function to date.

Using Mouse Avatars Aids Identification of Effective Targeted Therapies for Patients With Melanoma

Using Mouse Avatars Aids Identification of Effective Targeted Therapies for Patients With Melanoma

By

Using xenograft mice as avatars of patients with melanoma, scientists demonstrated that a previously ineffective targeted drug may halt disease progression in certain patients.

Progression-free Survival in Advanced Renal Cell Carcinoma Is Improved With Cabozantinib

By

Findings of the randomized, phase 3 METEOR trial demonstrate progression-free survival in patients with advanced renal cell carcinoma is improved with cabozantinib compared with everolimus.

Triple Therapy Shows Promise in Treatment Resistant Subtype of Lung Cancer

Triple Therapy Shows Promise in Treatment Resistant Subtype of Lung Cancer

By

Lung cancers with KRAS-related gene mutations might benefit from a triple therapy regimen of 2 experimental drugs plus radiation therapy.

New Breast Cancer Drug Showing Potential as a Treatment for Other Types of Cancer

New Breast Cancer Drug Showing Potential as a Treatment for Other Types of Cancer

By

Palbociclib, a new oral treatment for certain types of breast cancer, demonstrates potential as a treatment for other types of cancer as well.

Newly Identified Protein May Provide a Target for MYC Oncogene Activity in Several Cancers

By

Researchers identified a protein that is essential for MYC to cause cancer in mouse models, and they believe, could be a target for anticancer therapy.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs